Heterocyclic derivatives
The present invention relates to a heterocyclic derivative of formula (I) wherein the variables are as defined in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention further relates to pharmaceutical compositions comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of disorders mediated by glutamate dysfunction, such as schizophrenia and generalised anxiety disorder.
1. A heterocyclic derivative of formula I
wherein
R 1 is C 1-4 alkyl, C 0-4 alkylC 3-8 cycloalkyl, or C 0-4 alkylZ 1 , said C 1-4 alkyl and C 0-4 alkylC 3-8 cycloalkyl being optionally substituted with one or more substituent independently selected from hydroxy, C 1-4 alkyl, C 1 - 4 alkyloxy, CN and halogen;
Z 1 is a 4-7 membered saturated ring containing a heteroatom selected from O, S and SO 2 ;
n is 1 or 2;
each R 2 and R 3 is independently H or C 1-4 alkyl;
Y is O or NR 8 ;
R 4 , R 5 , R 6 and R 7 are independently H or C 1-4 alkyl; or
when Y is NR 8 , either R 4 and R 5 , or R 6 and R 7 , may together represent oxo;
R 8 is C 1-4 alkyl, C 0-4 alkylC 3-8 cycloalkyl, or C 0-4 alkylZ 2 , said C 1-4 alkyl and C 0-4 alkylC 3-8 cycloalkyl being optionally substituted with one or more substituent independently selected from hydroxy, C 1-4 alkyl, C 1 - 4 alkyloxy, oxo, CN and halogen;
Z 2 is a 4-7 membered saturated ring containing a heteroatom selected from O, S and SO 2 ;
X 1 -X 7 are CR 9 ; or one of X 1 -X 7 may be N;
each R 9 is independently selected from H, C 1-4 alkyl, C 1-4 alkyloxy, nitrile and halogen, said C 1-4 alkyl and C 1-4 alkyloxy being optionally substituted with one or more substituent independently selected from hydroxy and halogen;
R 10 and R 11 are independently H or C 1-4 alkyl; or, when R 10 is alkyl and X 1 is CR 9 , R 10 and R 9 together with the atoms to which they are bonded may form a fused ring optionally comprising a heteroatomic moiety selected from O, S and SO 2 ;
or a pharmaceutically acceptable salt thereof.
2. The heterocyclic derivative according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is C 1-4 alkyl or C 3-8 cycloalkyl.
3. The heterocyclic derivative according to claim 1 or a pharmaceutically acceptable salt thereof, wherein n is 1.
4. The heterocyclic derivative according to claim 1 or a pharmaceutically acceptable salt thereof, wherein each R 2 and R 3 is H.
5. The heterocyclic derivative according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 4 and R 5 are independently H or C 1-4 alkyl.
6. The heterocyclic derivative according to claim 5 or a pharmaceutically acceptable salt thereof, wherein Y is NR 8 and R 6 and R 7 together represent oxo.
7. The heterocyclic derivative according to claim 6 or a pharmaceutically acceptable salt thereof, wherein R 8 is C 1-4 alkyl or C 3-8 cycloalkyl.
8. The heterocyclic derivative according to claim 1 or a pharmaceutically acceptable salt thereof, wherein X 1 -X 7 are CR 9 and each R 9 is independently selected from H, C 1-4 alkyl, C 1-4 alkyloxy, nitrile and halogen, said C 1-4 alkyl or C 1-4 alkyloxy groups being optionally substituted with one or more halogen.
9. The heterocyclic derivative according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 10 and R 11 are H.
10. A heterocyclic derivative according to claim 1 selected from:
1-(4-(2-cyclopropyl-1-oxoisoindolin-5-yl)benzyl)-3-methylimidazolidine-2,4-dione;
1-(2-chloro-4-(2-cyclopropyl-1-oxoisoindolin-5-yl)benzyl)-3-ethylimidazolidine-2,4-dione;
1-(4-(2-cyclopropyl-1-oxoisoindolin-5-yl)benzyl)-3-ethyl-5,5-dimethylimidazolidine-2,4-dione;
1-(4-(7-chloro-2-(3-hydroxy-2,2-dimethylpropyl)-1-oxoisoindolin-5-yl)benzyl)-3-ethylimidazolidine-2,4-dione;
3-ethyl-1-(4-(1-oxo-2-(2,2,2-trifluoroethyl)isoindolin-5-yl)benzyl)imidazolidine-2,4-dione;
3-(4-(2-cyclopropyl-1-oxoisoindolin-5-yl)benzyl)-1-methylimidazolidine-2,4-dione;
2-cyclopropyl-5-(4-((3-methyl-2-oxoimidazolidin-1-yl)methyl)phenyl)isoindolin-1-one;
1-(2-chloro-4-(2-cyclopropyl-1-oxoisoindolin-5-yl)benzyl)-3-methylimidazolidine-2,4-dione;
1-(2-chloro-4-(1-oxo-2-(2,2,2-trifluoroethyl)isoindolin-5-yl)benzyl)-3-methylimidazolidine-2,4-dione;
1-(2-chloro-4-(2-(3-hydroxy-2,2-dimethylpropyl)-1-oxoisoindolin-5-yl)benzyl)-3 -methylimidazolidine-2,4-dione;
1-(2-chloro-4-(2-cyclopropyl-1-oxoisoindolin-5-yl)benzyl)-3,5,5-trimethylimidazolidine-2,4-dione;
1-(2-chloro-4-(1-oxo-2-(2,2,2-trifluoroethyl)isoindolin-5-yl)benzyl)-3,5,5-trimethylimidazolidine-2,4-dione;
1-(3-chloro-4-(2-cyclopropyl-1-oxoisoindolin-5-yl)benzyl)-3-methylimidazolidine-2,4-dione;
1-(3-chloro-4-(2-(3-hydroxy-2,2-dimethylpropyl)-1-oxoisoindolin-5-yl)benzyl)-3-methylimidazolidine-2,4-dione;
3,5,5-trimethyl-1-(4-(1-oxo-2-(2,2,2-trifluoroethyl)isoindolin-5-yl)benzyl)imidazolidine-2,4-dione;
1-(3-chloro-4-(2-cyclopropyl-1-oxoisoindolin-5-yl)benzyl)-3,5,5-trimethylimidazolidine-2,4-dione;
1-(3-chloro-4-(1-oxo-2-(2,2,2-trifluoroethyl)isoindolin-5-yl)benzyl)-3,5,5-trimethylimidazolidine-2,4-dione;
1-(4-(2-(3-hydroxy-2,2-dimethylpropyl)-1-oxoisoindolin-5-yl)benzyl)-3,5,5-trimethylimidazolidine-2,4-dione;
1-(4-(2-isopropyl-1-oxoisoindolin-5-yl)benzyl)-3-methylimidazolidine-2,4-dione;
1-(4-(2-cyclobutyl-1-oxoisoindolin-5-yl)benzyl)-3,5,5-trimethylimidazolidine-2,4-dione;
1-(4-(2-isobutyl-1-oxoisoindolin-5-yl)benzyl)-3,5,5-trimethylimidazolidine-2,4-dione;
1-(4-(2-cyclopropyl-1-oxoisoindolin-5-yl)benzyl)-3-ethylimidazolidine-2,4-dione;
3-methyl-1-(4-(1-oxo-2-(2,2,2-trifluoroethyl)isoindolin-5-yl)benzyl)imidazolidine-2,4-dione;
1-(4-(7-chloro-1-oxo-2-(2,2,2-trifluoroethyl)isoindolin-5-yl)benzyl)-3-methylimidazolidine-2,4-dione;
1-(4-(7-chloro-2-cyclopropyl-1-oxoisoindolin-5-yl)benzyl)-3-methylimidazolidine-2,4-dione;
3-ethyl-1-(4-(2-methyl-1-oxoisoindolin-5-yl)benzyl)imidazolidine-2,4-dione;
3-ethyl-1-(4-(2-isopropyl-1-oxoisoindolin-5-yl)benzyl)imidazolidine-2,4-dione;
3-ethyl-5,5-dimethyl-1-(4-(2-methyl-1-oxoisoindolin-5-yl)benzyl)imidazolidine-2,4-dione;
3-ethyl-1-(4-(2-ethyl-1-oxoisoindolin-5-yl)benzyl)-5,5-dimethylimidazolidine-2,4-dione;
3-ethyl-5,5-dimethyl-1-(4-(1-oxo-2-propylisoindolin-5-yl)benzyl)imidazolidine-2,4-dione;
3-ethyl-1-(4-(2-isopropyl-1-oxoisoindolin-5-yl)benzyl)-5,5-dimethylimidazolidine-2,4-dione;
1-(4-(2-ethyl-1-oxoisoindolin-5-yl)benzyl)-3-methylimidazolidine-2,4-dione;
3-methyl- 1-(4-(1-oxo-2-propylisoindolin-5-yl)benzyl)imidazolidine-2,4-dione;
3-ethyl- 1-(4-(2-ethyl-1-oxoisoindolin-5-yl)benzyl)imidazolidine-2,4-dione;
3-ethyl-1-(4-(1-oxo-2-propylisoindolin-5-yl)benzyl)imidazolidine-2,4-dione;
1-(4-(2-cyclobutyl-1-oxoisoindolin-5-yl)benzyl)-3-ethylimidazolidine-2,4-dione;
1-(4-(2-cyclobutyl-1-oxoisoindolin-5-yl)benzyl)-3-methylimidazolidine-2,4-dione;
1-(4-(2-isobutyl-1-oxoisoindolin-5-yl)benzyl)-3-methylimidazolidine-2,4-dione;
1-(4-(2-(cyclopropylmethyl)-1-oxoisoindolin-5-yl)benzyl)-3-ethylimidazolidine-2,4-dione;
1-(4-(2-(cyclopropylmethyl)-1-oxoisoindolin-5-yl)benzyl)-3-ethyl-5,5-dimethylimidazolidine-2,4-dione;
1-(4-(2-(cyclopropylmethyl)-1-oxoisoindolin-5-yl)benzyl)-3 -methylimidazolidine-2,4-dione;
3,5,5-trimethyl- 1-(4-(2-methyl-1-oxoisoindolin-5-yl)benzyl)imidazolidine-2,4-dione;
1-(4-(2-ethyl-1-oxoisoindolin-5-yl)benzyl)-3,5,5-trimethylimidazolidine-2,4-dione;
3,5,5-trimethyl- 1-(4-(1-oxo-2-propylisoindolin-5-yl)benzyl)imidazolidine-2,4-dione;
1-(4-(2-isopropyl-1-oxoisoindolin-5-yl)benzyl)-3,5,5-trimethylimidazolidine-2,4-dione;
1-(4-(2-(cyclopropylmethyl)- 1-oxoisoindolin-5-yl)benzyl)-3,5,5-trimethylimidazolidine-2,4-dione;
3,5,5-trimethyl-1-(4-(1-oxo-2-propyl-1,2,3,4-tetrahydroisoquinolin-6-yl)benzyl)imidazolidine-2,4-dione;
1-(4-(2-isopropyl-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)benzyl)-3,5,5-trimethylimidazolidine-2,4-dione;
(R)-3-(4-(2-cyclopropyl-1-oxoisoindolin-5-yl)benzyl)-5-methyloxazolidin-2-one;
(R)-3-(4-(2-(3-hydroxy-2,2-dimethylpropyl)-1-oxoisoindolin-5-yl)benzyl)-5-methyloxazolidin-2-one;
(R) -1-(1-(4-(2-cyclopropyl-1-oxoisoindolin-5-yl)phenyl)ethyl)-3-ethylimidazolidine-2,4-dione;
(R)-3-ethyl-1-(1-(4-(1-oxo-2-(2,2,2-trifluoroethyl)isoindolin-5-yl)phenyl)ethyl)imidazolidine-2,4-dione;
1-(5-(2-cyclopropyl-1-oxoisoindolin-5-yl)-2,3-dihydro-1H-inden- 1-yl)-3-ethylimidazolidine-2,4-dione;
3-ethyl-1-(5-(1-oxo-2-(2,2,2-trifluoroethyl)isoindolin-5-yl)-2,3-dihydro-1H-inden-1-yl)imidazolidine-2,4-dione;
3-cyclopropyl- 1-(4-(2-cyclopropyl-1-oxoisoindolin-5-yl)benzyl)imidazolidine-2,4-dione;
3-cyclopropyl- 1-(4-(2-(3-hydroxy-2,2-dimethylpropyl)-1-oxoisoindolin-5-yl)benzyl)imidazolidine-2,4-dione;
3-cyclopropyl-1-(4-(1-oxo-2-(2,2,2-rifluoroethyl)isoindolin-5-yl)benzyl)imidazolidine-2,4-dione;
1-(4-(2-cyclopropyl-1-oxoisoindolin-5-yl)benzyl)-3,5,5-trimethylimidazolidine-2,4-dione;
1-((5-(2-cyclopropyl-1-oxoisoindolin-5-yl)pyridin-2-yl)methyl)-3-methylimidazolidine-2,4-dione;
1-((5-(2-cyclopropyl-1-oxoisoindolin-5-yl)pyridin-2-yl)methyl)-3-isobutylimidazolidine-2,4-dione;
1-((6-(2-cyclopropyl-1-oxoisoindolin-5-yl)pyridin-3-yl)methyl)-3 -methylimidazolidine-2,4-dione;
3-methyl-1-((6-(1-oxo-2-(2,2,2-trifluoroethyl)isoindo lin-5-yl)pyridin-3-yl)methyl)imidazolidine-2,4-dione;
or a pharmaceutically acceptable salt thereof.
11. A method for treating schizophrenia or generalised anxiety disorder, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising a heterocyclic derivative according to claim 1 or a pharmaceutically acceptable salt thereof in admixture with one or more pharmaceutically acceptable excipient.